Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT)

Inder S. Anand, Lloyd D. Fisher, Yann Tong Chiang, Roberto Latini, Serge Masson, Aldo P. Maggioni, Robert D. Glazer, Gianni Tognoni, Jay N. Cohn

Research output: Contribution to journalArticle

659 Citations (Scopus)

Abstract

Background - Neurohormones are considered markers of heart failure progression. We examined whether changes in brain natriuretic peptide (BNP) and norepinephrine (NE) over time are associated with corresponding changes in mortality and morbidity in the Valsartan Heart Failure Trial. Methods and Results - Plasma BNP and NE were measured before randomization and during follow-up in ≈4300 patients in the Valsartan Heart Failure Trial. The relation between baseline BNP and NE and all-cause mortality and first morbid event (M&M) was analyzed in subgroups, with values above and below the median, and by quartiles. The change and percent change from baseline to 4 and 12 months in BNP and NE were also analyzed by quartiles for subsequent M&M. Risk ratios for M&M were calculated using a Cox proportional hazard model. Risk ratio of M&M for patients with baseline BNP or NE above the median was significantly higher than that for patients with values below the median. Baseline BNP and NE in quartiles also showed a quartile-dependent increase in M&M. BNP had a stronger association with M&M than NE. Patients with the greatest percent decrease in BNP and NE from baseline to 4 and 12 months had the lowest whereas patients with greatest percent increase in BNP and NE had the highest M&M. Conclusions - Not only are plasma BNP and NE important predictors of heart failure M&M, but changes in these neurohormones over time are associated with corresponding changes in M&M. These data further reinforce their role as significant surrogate markers in HF and underscore the importance of including their measurement in HF trials.

Original languageEnglish
Pages (from-to)1278-1283
Number of pages6
JournalCirculation
Volume107
Issue number9
DOIs
Publication statusPublished - Mar 11 2003

Fingerprint

Valsartan
Brain Natriuretic Peptide
Norepinephrine
Heart Failure
Morbidity
Mortality
Neurotransmitter Agents
Odds Ratio

Keywords

  • Heart failure
  • Natriuretic peptides
  • Norepinephrine
  • Trials, clinical

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). / Anand, Inder S.; Fisher, Lloyd D.; Chiang, Yann Tong; Latini, Roberto; Masson, Serge; Maggioni, Aldo P.; Glazer, Robert D.; Tognoni, Gianni; Cohn, Jay N.

In: Circulation, Vol. 107, No. 9, 11.03.2003, p. 1278-1283.

Research output: Contribution to journalArticle

Anand, Inder S. ; Fisher, Lloyd D. ; Chiang, Yann Tong ; Latini, Roberto ; Masson, Serge ; Maggioni, Aldo P. ; Glazer, Robert D. ; Tognoni, Gianni ; Cohn, Jay N. / Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). In: Circulation. 2003 ; Vol. 107, No. 9. pp. 1278-1283.
@article{a12d9bdcb5a04b3a8084634fbef7e5e9,
title = "Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT)",
abstract = "Background - Neurohormones are considered markers of heart failure progression. We examined whether changes in brain natriuretic peptide (BNP) and norepinephrine (NE) over time are associated with corresponding changes in mortality and morbidity in the Valsartan Heart Failure Trial. Methods and Results - Plasma BNP and NE were measured before randomization and during follow-up in ≈4300 patients in the Valsartan Heart Failure Trial. The relation between baseline BNP and NE and all-cause mortality and first morbid event (M&M) was analyzed in subgroups, with values above and below the median, and by quartiles. The change and percent change from baseline to 4 and 12 months in BNP and NE were also analyzed by quartiles for subsequent M&M. Risk ratios for M&M were calculated using a Cox proportional hazard model. Risk ratio of M&M for patients with baseline BNP or NE above the median was significantly higher than that for patients with values below the median. Baseline BNP and NE in quartiles also showed a quartile-dependent increase in M&M. BNP had a stronger association with M&M than NE. Patients with the greatest percent decrease in BNP and NE from baseline to 4 and 12 months had the lowest whereas patients with greatest percent increase in BNP and NE had the highest M&M. Conclusions - Not only are plasma BNP and NE important predictors of heart failure M&M, but changes in these neurohormones over time are associated with corresponding changes in M&M. These data further reinforce their role as significant surrogate markers in HF and underscore the importance of including their measurement in HF trials.",
keywords = "Heart failure, Natriuretic peptides, Norepinephrine, Trials, clinical",
author = "Anand, {Inder S.} and Fisher, {Lloyd D.} and Chiang, {Yann Tong} and Roberto Latini and Serge Masson and Maggioni, {Aldo P.} and Glazer, {Robert D.} and Gianni Tognoni and Cohn, {Jay N.}",
year = "2003",
month = "3",
day = "11",
doi = "10.1161/01.CIR.0000054164.99881.00",
language = "English",
volume = "107",
pages = "1278--1283",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT)

AU - Anand, Inder S.

AU - Fisher, Lloyd D.

AU - Chiang, Yann Tong

AU - Latini, Roberto

AU - Masson, Serge

AU - Maggioni, Aldo P.

AU - Glazer, Robert D.

AU - Tognoni, Gianni

AU - Cohn, Jay N.

PY - 2003/3/11

Y1 - 2003/3/11

N2 - Background - Neurohormones are considered markers of heart failure progression. We examined whether changes in brain natriuretic peptide (BNP) and norepinephrine (NE) over time are associated with corresponding changes in mortality and morbidity in the Valsartan Heart Failure Trial. Methods and Results - Plasma BNP and NE were measured before randomization and during follow-up in ≈4300 patients in the Valsartan Heart Failure Trial. The relation between baseline BNP and NE and all-cause mortality and first morbid event (M&M) was analyzed in subgroups, with values above and below the median, and by quartiles. The change and percent change from baseline to 4 and 12 months in BNP and NE were also analyzed by quartiles for subsequent M&M. Risk ratios for M&M were calculated using a Cox proportional hazard model. Risk ratio of M&M for patients with baseline BNP or NE above the median was significantly higher than that for patients with values below the median. Baseline BNP and NE in quartiles also showed a quartile-dependent increase in M&M. BNP had a stronger association with M&M than NE. Patients with the greatest percent decrease in BNP and NE from baseline to 4 and 12 months had the lowest whereas patients with greatest percent increase in BNP and NE had the highest M&M. Conclusions - Not only are plasma BNP and NE important predictors of heart failure M&M, but changes in these neurohormones over time are associated with corresponding changes in M&M. These data further reinforce their role as significant surrogate markers in HF and underscore the importance of including their measurement in HF trials.

AB - Background - Neurohormones are considered markers of heart failure progression. We examined whether changes in brain natriuretic peptide (BNP) and norepinephrine (NE) over time are associated with corresponding changes in mortality and morbidity in the Valsartan Heart Failure Trial. Methods and Results - Plasma BNP and NE were measured before randomization and during follow-up in ≈4300 patients in the Valsartan Heart Failure Trial. The relation between baseline BNP and NE and all-cause mortality and first morbid event (M&M) was analyzed in subgroups, with values above and below the median, and by quartiles. The change and percent change from baseline to 4 and 12 months in BNP and NE were also analyzed by quartiles for subsequent M&M. Risk ratios for M&M were calculated using a Cox proportional hazard model. Risk ratio of M&M for patients with baseline BNP or NE above the median was significantly higher than that for patients with values below the median. Baseline BNP and NE in quartiles also showed a quartile-dependent increase in M&M. BNP had a stronger association with M&M than NE. Patients with the greatest percent decrease in BNP and NE from baseline to 4 and 12 months had the lowest whereas patients with greatest percent increase in BNP and NE had the highest M&M. Conclusions - Not only are plasma BNP and NE important predictors of heart failure M&M, but changes in these neurohormones over time are associated with corresponding changes in M&M. These data further reinforce their role as significant surrogate markers in HF and underscore the importance of including their measurement in HF trials.

KW - Heart failure

KW - Natriuretic peptides

KW - Norepinephrine

KW - Trials, clinical

UR - http://www.scopus.com/inward/record.url?scp=0037432301&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037432301&partnerID=8YFLogxK

U2 - 10.1161/01.CIR.0000054164.99881.00

DO - 10.1161/01.CIR.0000054164.99881.00

M3 - Article

C2 - 12628948

AN - SCOPUS:0037432301

VL - 107

SP - 1278

EP - 1283

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 9

ER -